3Lee A gnes YY. Epidemiology and management of venous thromboembolism in patients with malignancy[ J ]. Thromb Res,2003,110 (4) : 167 - 172.
4Pao lo P, Andrea A, A ntonio G. Malignancy and venous thromboembolism: An overview [J] .Haematologica, 1999, 84 (4) :437 -445.
5M arcello De Cicco. The prothrombotic state in malignancy:pathogenic mechanisms[ J ]. Hematology ,2004,50( 1 ) : 187 - 196.
6Lee AYY, Levine MN. The thrombophilic state induced by therapeutic agents in the malignancy patient [ J ]. Semin Thromb Hemost, 1999,25 : 137 - 145.
7Geerts W, Pineo GF, Heit GA et al. Prevention of venous thromboembolism[J]. Chest,2004,126:338S - 400S.
8Bergqvist D, A gnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for malignancy[ J ]. N Engl JM,2002,346(13) :975 -980.
